US · NAGE
Niagen Bioscience Inc
- Sector
- Healthcare · Biotechnology
- Headquarters
- Los Angeles, CA 90024
- Website
- niagenbioscience.com
Price · as of 2024-12-31
$4.85
Market cap 403.02M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $34.60 | +613.4% |
| Intrinsic Value(DCF) | $18.09 | +272.99% |
| Graham-Dodd Method(GD) | $1.04 | -78.56% |
| Graham Formula(GF) | $2.65 | -45.32% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $5.40 | $80.61 | $18.77 | $0.00 | $0.00 |
| 2011 | $2.25 | $20.67 | $0.00 | $0.00 | $0.00 |
| 2012 | $2.40 | $44.77 | $8.33 | $0.00 | $0.00 |
| 2013 | $5.28 | $39.85 | $0.00 | $0.00 | $0.49 |
| 2014 | $4.11 | $35.99 | $17.54 | $0.00 | $0.00 |
| 2015 | $4.41 | $30.99 | $7.92 | $0.00 | $0.00 |
| 2016 | $2.72 | $26.63 | $15.03 | $0.00 | $0.00 |
| 2017 | $4.83 | $22.66 | $0.61 | $0.00 | $0.00 |
| 2018 | $3.54 | $27.42 | $0.80 | $0.00 | $0.00 |
| 2019 | $3.57 | $30.99 | $34.87 | $0.00 | $0.00 |
| 2020 | $11.75 | $35.49 | $110.72 | $0.00 | $0.00 |
| 2021 | $2.31 | $23.87 | $27.47 | $0.00 | $0.00 |
| 2022 | $1.48 | $29.35 | $2.73 | $0.00 | $0.00 |
| 2023 | $1.72 | $51.05 | $2.29 | $0.05 | $0.00 |
| 2024 | $7.70 | $34.60 | $5.40 | $1.04 | $2.65 |
AI valuation
Our deep-learning model estimates Niagen Bioscience Inc's (NAGE) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $34.60
- Current price
- $4.85
- AI upside
- +613.4%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$18.09
+272.99% upside
Graham-Dodd
$1.04
-78.56% upside
Graham Formula
$2.65
-45.32% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NAGE | Niagen Bioscience Inc | $4.85 | 403.02M | +613% | +273% | -79% | -45% | 76.93 | 14.27 | 6.60 | 66.87 | — | 14.38 | 61.84% | 7.76% | 8.58% | 22.94% | 169.60% | 13.88% | 0.06 | — | 3.57 | 2.91 | -4.54 | -26692.00% | 1918.00% | 7142.00% | 1.82% | 0.67 | 271.59% | 0.00% | 0.00% | 2.73% | 79.72 | 51.56 | 6.18 | 16.70 |
| AKBA | Akebia Therapeutics, Inc. | $1.31 | 347.63M | +2,616% | +600% | — | — | -60.62 | 9.94 | 1.37 | -56.76 | — | -12.26 | 83.29% | 9.95% | -2.26% | 64.49% | -72.80% | -1.79% | 0.00 | 0.97 | 1.13 | 1.42 | 75.38 | -9370.00% | 4746.00% | -26637.00% | 20.89% | 0.42 | -209.73% | 0.00% | 0.00% | 99.29% | 5.92 | 2.06 | 0.59 | -4.79 |
| CRVS | Corvus Pharmaceuticals, I… | $18.26 | 1.53B | — | — | — | — | -4.52 | 8.65 | — | -8.41 | -5.57 | 8.65 | 0.00% | — | — | -174.85% | 1026.95% | -108.85% | 0.03 | — | 1.54 | 1.47 | 0.28 | 8124.00% | — | 607.00% | -9.02% | -0.72 | 947.77% | 0.00% | 0.00% | 0.00% | -8.38 | -9.08 | — | -4.40 |
| KALV | KalVista Pharmaceuticals,… | $16.28 | 822.89M | — | — | — | — | -3.93 | 7.56 | — | -3.11 | -54.08 | 7.56 | 0.00% | — | — | -121.50% | 456.02% | -75.46% | 0.07 | -32.50 | 5.35 | 4.49 | 0.53 | 727.00% | — | 7100.00% | -21.27% | -3.39 | 371.96% | 0.00% | 0.00% | 9.41% | -2.87 | -3.52 | — | -2.40 |
| KROS | Keros Therapeutics, Inc. | $14.19 | 575.24M | +2,117% | -32% | — | — | -2.27 | 0.75 | 120.01 | 0.62 | — | 0.75 | 100.00% | -5938.96% | -5277.55% | -41.46% | -916.80% | -38.01% | 0.03 | — | 21.45 | 20.56 | 2.91 | -385.00% | 225099.00% | 2822.00% | -38.21% | -5.86 | -707.93% | 0.00% | 0.00% | 52.66% | 0.55 | 0.71 | -32.40 | 4.44 |
| OLMA | Olema Pharmaceuticals, In… | $24.20 | 1.9B | — | — | — | — | -2.09 | 0.66 | — | 1.14 | -74.60 | 0.66 | 0.00% | — | — | -39.07% | 974.77% | -35.57% | 0.00 | — | 10.50 | 10.45 | 0.97 | 280.00% | — | 2482.00% | -38.59% | -2.50 | 716.12% | 0.00% | 0.00% | 26.56% | 1.14 | 1.55 | — | 2.53 |
| PRTA | Prothena Corporation plc | $8.67 | 466.71M | +225% | -47% | — | +4,117% | -2.07 | 1.80 | 52.25 | -1.06 | -2.08 | 1.80 | 0.00% | -1905.82% | -2520.57% | -63.62% | -2799.76% | -55.86% | 0.05 | — | 7.72 | 7.53 | 1.46 | 9956.00% | -9283.00% | 889.00% | -32.36% | -4.01 | -2483.59% | 0.00% | 0.00% | 0.00% | -1.15 | -1.30 | 21.92 | 5.73 |
| RGNX | REGENXBIO Inc. | $9.04 | 457.63M | +97% | -72% | — | — | -1.38 | 1.21 | 3.77 | -0.81 | — | 1.21 | 59.72% | -280.03% | -272.54% | -79.49% | -200.49% | -43.68% | 0.32 | -18.43 | 2.69 | 2.48 | -0.12 | -2375.00% | -766.00% | -2312.00% | -55.93% | -1.68 | -150.84% | 0.00% | 0.00% | 10.02% | -0.69 | -0.92 | 1.93 | -2.91 |
| RIGL | Rigel Pharmaceuticals, In… | $34.74 | 630.58M | +1,555% | +15% | -85% | +70% | 20.63 | 109.71 | 2.01 | 12.04 | — | -15.15 | 89.60% | 13.49% | 9.75% | -137.92% | -117.91% | 12.44% | 18.24 | 3.06 | 2.13 | 1.88 | 0.11 | -16875.00% | 5338.00% | -24981.00% | 8.61% | 0.50 | -159.09% | 0.00% | 0.00% | 9.58% | 14.19 | 11.05 | 1.92 | -8.42 |
| VTYX | Ventyx Biosciences, Inc. | $13.97 | 1B | — | — | — | — | -0.76 | 0.40 | — | 0.71 | — | 0.40 | 0.00% | — | — | -54.27% | -573.99% | -48.76% | 0.04 | — | 17.97 | 17.09 | 0.11 | -4030.00% | — | -2151.00% | -128.50% | -10.24 | -506.96% | 0.00% | 0.00% | 0.00% | 0.70 | 0.80 | — | -0.92 |
| ZVRA | Zevra Therapeutics, Inc. | $8.93 | 502.74M | +120% | +12,185% | — | +34% | -3.55 | 9.44 | 15.87 | -4.78 | -4.71 | -11.01 | 68.59% | -368.47% | -446.85% | -207.84% | -254.55% | -60.21% | 1.52 | -11.84 | 2.53 | 2.35 | -0.35 | 7538.00% | -1402.00% | 10592.00% | -18.60% | -2.05 | -203.82% | 0.00% | 0.00% | 0.00% | -4.20 | -5.25 | 15.48 | -3.48 |
About Niagen Bioscience Inc
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
- CEO
- Robert N. Fried
- Employees
- 104
- Beta
- 2.09
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($18.09 ÷ $4.85) − 1 = +272.99% (DCF, example).